Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28862348 | 1.00 | DYRK1A (0.57) | DYRK1APKMFLT3MIFIRAK4 | |
| SCHEMBL15757581 | 0.78 | FLT3 (0.68) | DYRK1APKMFLT3MIFIRAK4 | |
| SCHEMBL1615002 | 0.75 | MAP3K14 (0.62) | DYRK1AFLT3 | |
| SCHEMBL34464684 | 0.75 | PKM (0.57) | DYRK1APKMFLT3MIFIRAK4 | |
| SCHEMBL22919154 | 0.75 | PKM (0.57) | DYRK1APKMFLT3MIFIRAK4 | |
| SCHEMBL29615472 | 0.75 | PKM (0.50) | DYRK1APKMFLT3MIFIRAK4 | |
| SCHEMBL700671 | 0.75 | PKM (0.50) | DYRK1APKMFLT3MIFIRAK4 | |
| SCHEMBL182990 | 0.75 | DYRK1A (0.66) | DYRK1APKMFLT3IRAK4MAPK8 | |
| SCHEMBL4804170 | 0.75 | DYRK1A (0.66) | DYRK1APKMFLT3IRAK4MAPK8 | |
| SCHEMBL16796241 | 0.74 | FLT3 (0.57) | DYRK1APKMFLT3MIFIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955500-A | 4- (Imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118955500-A | 4- (Imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118955500-A | 4- (Imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-114174293-B | 4- (Imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4003992-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174293-A | 4- (imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114174293-A | 4- (imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2022-03-11 | — | — | CN | disclosed |